Kuranda Klaudia, Caillat-Zucman Sophie, You Sylvaine, Mallone Roberto
INSERM, U1016, Cochin Institute, Paris 75014, France.
CNRS, UMR8104, Cochin Institute, Paris 75014, France.
Mol Ther Methods Clin Dev. 2018 Dec 31;13:112-120. doi: 10.1016/j.omtm.2018.12.010. eCollection 2019 Jun 14.
Hematopoietic stem cell transplantation (HSCT) using unrelated cord blood (CB) donors is a suitable approach when an HLA-matched donor is not available. However, one important drawback is the risk of life-threatening viral infections prior to immune reconstitution, particularly from adenoviruses (AdVs). Although adoptive therapy with expanded virus-reactive donor T cells has proven effective to treat these infections in HSCT recipients, the manufacturing process is complex and requires large numbers of cells, which is incompatible with CB donor units. Here, we have adapted our previous accelerated co-cultured dendritic cell (acDC) method, which allows to efficiently and rapidly expand peripheral blood T cells reactive to a given antigen, for use on limited CB material. Selected cytokine cocktails induced DC differentiation and maturation from unfractionated CB mononuclear cell cultures and simultaneously stimulated and expanded, within 10 days, functional CD8 T cells specific for the model antigen MelanA or AdV immunodominant peptides. In addition, the use of G-Rex cultures yielded numbers of AdV-reactive CD8 T cells compatible with adoptive cell therapy applications. Our acDC strategy, which uses reagents compatible with good manufacturing practices, may be promptly translated into the clinic for treating intercurrent infections in CB HSCT recipients.
当无法获得 HLA 匹配的供体时,使用无关脐血(CB)供体进行造血干细胞移植(HSCT)是一种合适的方法。然而,一个重要的缺点是在免疫重建之前存在危及生命的病毒感染风险,尤其是来自腺病毒(AdV)的感染。尽管采用扩增的病毒反应性供体 T 细胞进行过继性治疗已被证明对治疗 HSCT 受者的这些感染有效,但制造过程复杂且需要大量细胞,这与 CB 供体单位不兼容。在此,我们改进了我们之前的加速共培养树突状细胞(acDC)方法,该方法能够有效且快速地扩增对给定抗原反应的外周血 T 细胞,以用于有限的 CB 材料。选定的细胞因子组合可诱导未分离的 CB 单核细胞培养物中的 DC 分化和成熟,并在 10 天内同时刺激和扩增对模型抗原 MelanA 或 AdV 免疫显性肽具有特异性的功能性 CD8 T 细胞。此外,使用 G-Rex 培养物产生的 AdV 反应性 CD8 T 细胞数量与过继性细胞治疗应用兼容。我们的 acDC 策略使用符合良好生产规范的试剂,可能会迅速转化为临床应用,用于治疗 CB HSCT 受者的并发感染。